 BASEL, Switzerland, Jan. 05, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV, a healthcare company focused on redefining care for women and for men, today announced that ORGOVYXTM relugolix, the first and only oral gonadotropin-releasing hormone GnRH receptor antagonist approved by the U.S. Food and Drug Administration FDA for the treatment of adult patients with advanced prostate cancer, is now available through authorized specialty distributors. 